Interleukin-18 (IL-18) plays a key role in both, the innate and adaptive immune response (1). In addition, IL-18 is implicated in NK activation and Th1 cell differentiation. The role of IL-18, as an anti-cancer agent is substantiated by different mechanisms that include upregulation of Fas ligand (FasL) expression on NK cells and CTL resulting in tumor apoptosis, activation of NK cells, and generation of CTLs that can mediate anti-tumor activity and form an important part of immunological memory (see cartoon representing IL-18 mechanism of action). Single agent IL-18 demonstrated profound anti-tumor activity when administered at high doses in mice bearing late, well-established MOPC-315 tumor (2).
Introduction
IL-18 is a pleiotrophic cytokine that has the capability to stimulate innate immunity and both Th1-and Th2-mediated responses. As amember of the IL-1 family it contributes to host defense. IL-18 is synthesized as a precursor that needs to be processed to mature active form by intracellular cystein protease IL-1β-converting enzyme (ICE) and is produced by a wide range of cells, but mainly by activated macrophages, T cells, dendritic cells and Kupffer cells (3) . The IL-18 receptor system and its signal transduction pathway are analogous to those of the IL-1 receptor (4). In conclusion, depending upon the cell type, IL-18 may be an inducer of Th1 and/or Th2 -type cytokines.
Anti-Tumor Activity of IL-18 in Pre-Clinical Models
As a single agent, recombinant murine IL-18 has demonstrated antitumor activity in two advanced immunosensitive tumor models, the MOPC-315 plasmacytoma and the T cell lymphoma, EL-4. In the MOPC-315 tu-mor model, IL-18 eradicated advanced (100-150 cu mm2) tumors at doses ranging from 0.5 to 5.0 mg/kg, administered subcutaneously, on a qd × 28 schedule. In animals transplanted with EL-4 T cell lymphoma, an aggressive ascites-producing tumor, protracted daily treatment with IL-18 (qd × 30. 3.0-6.0 mg/kg) prolonged life span by >360%. In vivo administration of IL-18 induced activation of the transcription factor, NFκB, resulting in the production of other cytokines, including interferon gamma (IFNγ ) and GM-CSF, activation of cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs) and induction of IL-18 binding protein (IL-18BP). To further understand the mechanisms of IL-18 anti-tumor activity, tumor tissues were profiled by immunohistochemistry and splenocytes were characterized by flow cytometry from IL-18 treated and untreated mice. Following IL-18 administration, increased numbers of NK cells, CD8-positive T cells (CTLs) and dendritic cells (DCs) were observed in tumor tissues. Flow cytometry of the splenocytes revealed an increase in activated (CD69-positive) NK and CD8 cells and an increase in CD11b, CD11c-positive cells and an increase in FasL expression. Significant loss of anti-tumor activity with a high dose regimen of IL-18 was observed in T/B cell deficient SCID mice whereas activity was retained in mice depleted of NK cells by anti-asialo GM1. Consistent with this result, mice that were cured of tumor burden were also protected from a subsequent tumor challenge. These data, taken together, suggest at least a partial dependence of IL-18 anti-tumor activity on T-cell mediated induction of immunological signaling and "memory" in the syngeneic tumor models studied.
SB 485232 in Cancer Therapy
Recombinant human IL-18 is currently in Phase I clinical trials. Consistent with the preclinical data, induction of Th1 cytokines (e.g., GM-CSF, interferon gamma (IFNγ )) in sera as well as activation of NK cells and CD8 lymphocytes in peripheral blood was observed in cancer patients treated with recombinant human IL-18 (Proc. ASCO 22:713a 2003). The correlation between IL-18 induced biomarkers in pre-clinical tumor models and cancer patients treated in Phase I studies suggests the potential relevance of syngenic tumor models in better understanding the anti-tumor mechanisms of IL-18 as well as utilizing such models to discover possible surrogate markers for response.
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ABSTRACTS TOXICOLOGIC PATHOLOGY
In summary IL-18 anti-tumor activity is associated with a cellular immune response characterized by activation of CTLs, NKs and DCs with subsequent tumor infiltration. The increased expression of Fas ligand on activated lymphocytes and the enhanced production of Th1 cytokines, such as GM-CSF and IFNγ , may be important mechanism, which enhances cellular anti-tumor immunity. Additional anti-tumor mechanisms of IL-18 may include inhibition of tumor angiogenesis. In pre-clinical murine tumor models, advanced MOPC-315 and EL-4 regress completely in response to protracted IL-18 exposure, suggesting a potential role in the treatment of immunosensitive tumors. The correlation between these molecular events and the anti-tumor activity of IL-18 will be discussed.
The Treatment of Drug Resistant Leukemias and Lymphomas with Recombinant Immunotoxins
IRA PASTAN, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA Antibody based therapies of cancer have become increasingly important over the last several years. Some antibodies like Rituxan, Herceptin and Campath are able to kill cancer cells and cause significant tumor regressions when administered by themselves. However, many antibodies are ineffective and must be armed with a cytotoxic substance to kill cells. Our laboratory has used the powerful bacterial toxin, Pseudomonas exotoxin A (PE), for this purpose. Our strategy is to replace the binding domain of the toxin with the Fv portion of a tumor specific antibody. The resulting molecule, called a recombinant immunotoxin (RIT), can be economically produced in E. coli. Several different RITs have been produced and are now being evaluated in clinical trials. The most active of these is BL22. BL22 is composed of the Fv portion of an antibody that reacts with CD22 fused to a 38-kDa fragment of PE. CD22 is a differentiation antigen expressed on the surface of B cells and most B cell malignancies. It is a good target for immunotherapy because it is not expressed on any other cell type and is also not expressed on B cell precursors so normal B cells can be regenerated if they are killed.
BL22 was evaluated in a phase 1 trial in patients with Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), and non-Hodgkin's lymphoma. Even though this was a phase 1 dose escalation trial, the majority of patients with HCL achieved a complete remission in which tumor cells were undetectable and their pancytopenias were corrected. BL22 had less activity in CLL reflecting the fact that CLL cells have fewer receptors than cells from patients with HCL.
To make an immunotoxin that could be useful for treating CLL we used antibody phage display to increase the affinity of BL22. Using this technique we produced a mutant immunotoxin (HA22) that has a 10-fold increased affinity for CD22 and is cytotoxic to cells from patients with CLL. HA22 is now being prepared for a phase 1 trial in patients with CLL.
